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The role and potential efﬁcacy of antithymocyte globulin (ATG) in patients receiving cord blood trans-
plantation (CBT) remain controversial. We retrospectively evaluated the effect of ATG on patient outcomes in
207 childrenwith high-risk or advanced hematological malignancies at 8 child blood disease centers in China.
The cumulative incidence of platelet recovery on day 100 was signiﬁcantly lower in the ATG cohort compared
with the non-ATG cohort (77.3% versus 89.8%) (P ¼ .046). There was no signiﬁcant difference in the incidence
of grade II to IV acute and chronic graft-versus-host disease (GVHD), and transplantation-related mortality
(TRM) between the 2 groups (P ¼ .76, P ¼ .57, and P ¼ .46, respectively). The incidence of CMV infection was
signiﬁcantly higher among the ATG group compared with that among the non-ATG group (P ¼ .003). The 5-
year cumulative incidence of relapse was signiﬁcantly higher in the ATG cohort (30.7% versus 15.4%)
(P ¼ .009). Overall survival in the non-ATG group was slightly higher than that of the ATG cohort (64.1% versus
52.1%, P ¼ .093) and leukemia-free survival in the non-ATG cohort was signiﬁcantly higher than in the ATG
cohort (56.6% versus 37.7%, P ¼ .015). Our study demonstrated that, for high-risk or advanced childhood
hematological malignancies receiving unrelated CBT, patients who received conditioning that omitted ATG
had a faster platelet recovery, a comparable GVHD and TRM, a signiﬁcantly lower relapse risk, and an
improved long-term survival compared with those patients who received ATG in the conditioning.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host disease (GVHD) is the most
important cause of death after allogeneic (allo) hematopoi-
etic stem cell transplantation (HSCT), and antithymocyte
globulin (ATG) has been used in the conditioning regimens to
prevent the severe GVHD in this setting. Cord blood (CB)
transplantation (CBT) is an effective and potential curativedgments on page 712.
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ty for Blood and Marrow Transplantation.treatment for pediatric patients with hematological malig-
nancies who lack HLA-identical related or unrelated donors.
Several randomized controlled clinical trials reported that
ATG-containing regimens lowered the risk of GVHD signiﬁ-
cantly compared with ATG-omitted regimens in the unre-
lated or mismatched allo-HSCT [1-5]. However, the role and
potential efﬁcacy of ATG in patients receiving CBT remains
controversial. Most clinical studies demonstrated that inci-
dence and severity of acute GVHD are lower in pediatric or
adult CBT recipients compared with recipients of allo-HSCT
from unrelated or mismatched donors [6-10]. This observa-
tion may be related to the 10-fold fewer T cells used in CBT
and the predominantly naïve phenotype of CB T cells, which
Table 1
Patient and Transplantation Characteristics
Characteristics ATG (n ¼ 98) Non-ATG
(n ¼ 109)
P
Age at transplantation,
median (range), yr
6.9 (1-17) 9.7 (3-17) .26
Sex: male/female 63/35 72/37 .95
Underlying disease, n (%) .78
ALL 43 (43.9) 49 (44.9)
AML 40 (40.8) 48 (44.1)
CML 7 (7.1) 6 (5.5)
Others* 8 (8.2) 6 (5.5)
Disease stage in
transplantation
.66
CR1 71 (72.4) 68 (62.4)
CR2 21 (21.4) 24 (22.1)
Primary induction failure or
no remission after relapse
6 (6.2) 17 (15.5)
CNS involvement 4 (4.1) 8 (7.3) .35
HLA match (lowest) .59
6/6 15 (15.3) 21 (19.3)
5/6 62 (63.3) 68 (62.4)
4/6 21 (21.4) 20 (18.3)
ABO compatibility .14
Match 24 (24.5) 46 (42.2)
Major mismatch 35 (35.7) 22 (20.2)
Minor mismatch 39 (39.7) 41 (37.6)
Myeloablative conditioning
regimen
.012
BUCY2-based conditioning 77 (78.6) 71 (65.2)
BUCY2BCNU 38 6
BUCY2þHDACBCNU 10 23
BUCY2þFluBCNU 9 32
BUCY2þVP16CCNU 7 2
BUCY2þFluHDACMel 13 8
TBICY-based conditioning 17 (17.3) 36 (33.0)
TBICYBCNU 7 3
TBICYþHDACBCNU 1 31
TBICYþFluþVP16Mel 9 2
Othersy 4 (4.1) 2 (1.8)
GVHD prophylaxis <.001
CSA 27 (27.6) 2 (1.8)
CSAþMMF 15 (15.3) 92 (84.4)
CSAþMMFþMTXMP 26 (26.5) 7 (6.4)
CSAþMPMTX 17 (17.3) 3 (2.8)
CSAþMTXFK506 10 (10.2) 3 (2.8)
CSAþSIR 3 (3.1) 2 (1.8)
Total nucleated cell dose,
median (range), 107/kg
5.12 5.42 .43
Total CD34þ cell dose,
median (range), 105/kg
3.82 2.94 .17
Graft source .016
Single CB 82 (83.7) 103 (94.5)
Double CB 16 (16.3) 6 (5.5)
Follow-up among survivors,
median (range), mo
39 (15-154) 41 (16-152) .82
ALL indicates acute lymphoblastic leukemia; CML, chronic myeloid leuke-
mia; CR, complete remission; CNS, central nervous system; BU, busulfan; CY,
cyclophosphamide; BCNU, carmustine; HDAC, high-dose cytarabine; Flu,
ﬂudarabine; VP16, etoposide; CCNU, lomustine; Mel, melphalan; CSA,
cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate; MP,
methylprednisolone; FK506, tacrolimus; SIR, sirolimus.
Data presented are n (%) unless otherwise indicated.
* Others include juvenile myelomonocytic leukemia (n ¼ 5), mixed acute
leukemia (n ¼ 2), and MDS (n ¼ 1) in the ATG group, and juvenile myelo-
monocytic leukemia (n¼ 1), mixed acute leukemia (n¼ 2), MDS (n¼ 2), and
non-Hodgkin’s lymphoma (n ¼ 1) in the non-ATG group.
y Others include MelþFlu (n ¼ 1), CYþFlu (n ¼ 1), TBIþMel (n ¼ 1) and
TBIþMelþFlu (n¼ 1) in the ATG group, and TBIþMelþFlu (n¼ 2) in the non-
ATG group.
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properties [11]. However, the delayed T cell reconstitution
after CBT can potentially lead to increased risk for severe
infections, and this would be aggravated by the use of ATG as
a regimen for the in vivo T cell depletion. Another concernabout the use of ATG in CBT may be a decrease in the graft-
versus-leukemia (GVL) effect and an increase in the relapse
incidence after transplantation due to the delayed immune
reconstitution. In the present study, we retrospectively
compared the outcomes of routine GVHD prophylaxis
(cyclosporine-based regimens) plus pretransplantation ATG
(ATG group) to routine GVHD prophylaxis alone (non-ATG
group) in children with high-risk or advanced hematological
malignancies receiving unrelated CBT.
PATIENTS AND METHODS
Patient Eligibility and Cord Blood Selection
The study included patients younger than 18 years at transplantation
with hematological malignancies who received unrelated CBT between
February 2000 and August 2013 at 8 child blood disease centers in China.
These hematological malignancies included acute lymphoblastic leukemia,
acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic
syndrome (MDS), juvenile myelomonocytic leukemia, and non-Hodgkin
lymphoma, regardless of disease status at transplantation.
All of the childhood hematological malignancies patients who were
referred for transplantation had at least 1 of the following high-risk features:
(1) patients with acute leukemia were in ﬁrst complete remission but have
high-risk factors at ﬁrst diagnosis, which we had been reported previously
[12]; that is, acute lymphoblastic leukemia with adverse cytogenetics or
molecular abnormalities (ph þ chromosome [BCR-ABL positive], hypodip-
loidy,11q23 abnormalities [mixed lineage leukemia {MLL} rearrangements])
or with a high level of minimal residual disease (1% ormore after completion
of 6 weeks of induction therapy); AML with adverse cytogenetics or molec-
ular abnormalities (inv(3)(q21q26.2) or t(3;3)(q21;q26.2), t(6;9)(p23;q34),
11q23 abnormalities [MLL rearrangements], -5 or del(5q), -7 or del(7q),
complex karyotype, normal cytogenetics with FLT3-ITD mutation), or prior
historyofMDS; (2) second complete remission or greater; (3)MDS-refractory
anemia with excess blasts, juvenile myelomonocytic leukemia, chronic
myeloid leukemia in accelerated phase or in blast crisis; or (4) primary in-
duction failure or no remission after relapse with salvage chemotherapy
(including non-Hodgkin lymphoma).
CBT was performed if no suitable related donor was available and the
patients were regarded as having early transplantation without sufﬁcient
time for an unrelated bone marrow donor search. CB units that were sero-
logically matched for  4 of 6 HLA antigens and which contained at least
3  107 nucleated cells/kg and 1.2  105 CD34þ/kg of recipient body weight
before freezing were obtained from China Cord Blood Bank (including Bei-
jing Cord Blood Bank, Shanghai Cord Blood Bank, Sichuan Cord Blood Bank,
Guangzhou Cord Blood Bank, Shandong Cord Blood Bank, Zhejiang Cord
Blood Bank, and Hong Kong Cord Blood Bank). Patients receiving CBT as a
second transplant after relapse after a ﬁrst auto- or allogeneic trans-
plantation were excluded.
Transplantation Procedures
Patients were divided into 2 groups: those who received ATG and those
who did not receive ATG in their conditioning regimens (Table 1). The ATG
used was at a total dose of 7.5 to 10 mg/kg (Thymoglobulin, Genzyme, Paris,
France) or 18 to 20 mg/kg (ATG-F, Fresenius Biotech, Graefelﬁng, Germany)
between days -5 and -2. In the ATG cohort (n ¼ 98), 94 (95.9%) patients
received myeloablative conditioning of BUCY2-based (busulfan [.8 mg/kg
every 6 hours for 4 days] and cyclophosphamide [60mg/kg daily for 2 days])
(n¼ 77, 78.6%) or TBICY-based (total body irradiation [total 12Gy, 4 fractions]
and cyclophosphamide [60 mg/kg daily for 2 days]) regimens (n¼ 17, 17.3%).
In the non-ATG cohort (n¼ 109), 107 (98.2%) patients received BUCY2-based
(n ¼ 71, 65.2%) or TBICY-based (n ¼ 36, 33%) myeloablative conditioning.
High-dose cytarabine, etoposide, ﬂudarabine, melphalan, carmustine, or
lomustine were added to the myeloablative conditioning regimen to kill the
leukemia cells maximally, especially in extramedullary sites. For GVHD
prophylaxis, all patients received cyclosporine A starting at 2.5 to 3 mg⁄kg
intravenously daily on day1 with target trough levels 200 to 250 ng/mL, or
in combination with mycophenolate mofetil (25 to 30 mg/kg/day), methyl-
prednisolone (1mg/kg), or short-coursemethotrexate (7 to 15mg/m2 on day
1 and 7 to 10 mg/m2 on days 3, 6, and/or 11), etc. Although the conditioning
and GVHD prophylaxis regimens differed among the 8 centers, each center
adhered to their own constant approaches throughout the study period.
Deﬁnitions and Statistical Analysis
Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days
with an absolute neutrophil count  .5  109⁄L and platelet engraftment was
deﬁned as the ﬁrst day when the platelet count was  20  109⁄L for 7
consecutive days without transfusion support. Primary graft failure was
Figure 1. (A) Engraftment and acute GVHD. The cumulative incidence of
neutrophil recovery by day 42 was 91.2% (95% CI, 86.4% to 96.5%) in the ATG
cohort and 90.8% (95% CI, 85.6% to 95.9%) in the non-ATG cohort (P ¼ .62), and
the cumulative incidence of platelet recovery on day 100 was signiﬁcantly
lower in the ATG cohort as compared with the non-ATG cohort (77.3% [95% CI,
68.6% to 86.3%] versus 89.8% [95% CI, 82.9% to 94.2%]) (P ¼ .046). (B) The cu-
mulative incidences of grade II to IV aGVHD in the ATG and non-ATG cohorts
were 26.7% (95% CI, 19.6% to 33.2%) and 30.5% (95% CI, 24.8% to 36.5%),
respectively (P ¼ .76), and the cumulative incidences of severe aGVHD (grades
3 and 4) in the ATG and non-ATG cohorts were 13.3% (95% CI, 6.4% to 19.8%)
and 14.6% (95% CI, 8.7% to 21.6%), respectively (P ¼ .83).
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without donor-derived cells on day 42 or reconstitution with autologous
cells. Both acute and chronic GVHD (aGVHD and cGVHD) were diagnosed
and graded according to the previously published criteria [13,14]. Trans-
plantation-related mortality (TRM) was deﬁned as death from any cause
other than recurrent malignancy, and time to TRM was deﬁned as the
number of days from transplantation to death without preceding relapse.
Relapse was deﬁned by the morphological evidence of disease in the pe-
ripheral blood, bone marrow, or extramedullary sites, and time to relapse
was deﬁned as the number of days from transplantation to the ﬁrst diag-
nosis of relapse.Overall survival (OS) was deﬁned as the number of days from
transplantation to death of any cause, and leukemia-free survival (LFS) was
deﬁned as the number of days from transplantation to the ﬁrst diagnosis of
relapse or death. Variables of the 2 transplantation groups were compared
via chi-square test (categorical covariates) or Mann-Whitney U-test
(continuous covariates). Time-to-event outcomes for neutrophil and platelet
engraftment, GVHD, TRM, and relapse were estimated using cumulative
incidence curves, and these analyses were performed with R statistical
software (R Foundation for Statistical Computing, Vienna, Austria) because
of the presence of competing risks. For neutrophil or platelet engraftment
and GVHD, death without an event was the competing risk; for TRM, relapse
was the competing event, and for relapse, TRM was the competing event.
The probabilities of the OS and LFS were calculated using the Kaplan-Meier
method, and these analyses were performed with SPSS (version 17.0). Dif-
ferences at P < .05 were considered signiﬁcant.
RESULTS
Engraftment and GVHD
Eighteen patients (8 in the ATG group and 10 in the non-
ATG group) had primary graft failure. Rates of neutrophil
engraftment were similar among ATG and non-ATG patients.
The cumulative incidence of neutrophil recovery by day 42
was 91.2% (95% conﬁdence interval [CI], 86.4% to 96.5%) in the
ATG cohort and 90.8% (95% CI, 85.6% to 95.9%) in the non-ATG
cohort (P ¼ .62). Patients achieved neutrophil engraftment in
a median time of 17.2 days (range, 10 to 44) in the ATG group
and 18.5 days (range, 9 to 37) in the non-ATG group (P ¼ .16).
The cumulative incidence of platelet recovery on day 100
was signiﬁcantly lower in the ATG cohort than in the non-
ATG cohort (77.3% [95% CI, 68.6 to 86.3] versus 89.8% [95%
CI, 82.9 to 94.2], P ¼ .046). These platelet engraftments
occurred at 40.5 days (range, 17 to 91 days) and 38.5 days
(range, 17 to 94 days) for the ATG and non-ATG patients,
respectively (Figure 1A).
There was no difference in the incidence of aGVHD be-
tween the 2 groups. At day 100 after transplantation, the
cumulative incidences of grade II to IV aGVHD in the ATG and
non-ATG cohorts were 26.7% (95% CI, 19.6% to 33.2%) and
30.5% (95% CI, 24.8% to 36.5%), respectively (P ¼ .76). The
cumulative incidences of severe aGVHD (grades III and IV) in
the ATG and non-ATG cohorts were 13.3% (95% CI, 6.4% to
19.8%) and 14.6% (95% CI, 8.7% to 21.6%), respectively (P¼ .83)
(Figure 1B). Among patients who survived more than
100 days, the cumulative incidence of cGVHD (including local
and extensive-type cGVHD) at 2 years after transplantation
did not signiﬁcantly differ between the ATG and the non-ATG
cohorts (15.2% [95% CI, 10.6% to 20.8%] versus 18.3% [95% CI,
11.9% to 25.3%], P ¼ .57).
TRM and Relapse
Death from treatment-related complications occurred in
33 of 98 recipients of the ATG cohort, and in 30 of 109 re-
cipients of the non-ATG cohort. TRM was not signiﬁcantly
different between the 2 groups: the cumulative incidence of
TRM by day 180 was 32.1% (95% CI, 25.5% to 37.8%) and 28%
(95% CI, 23.7% to 33.6%) in the ATG and non-ATG cohorts
(P ¼ .46) (Figure 2A). Bacterial or invasive fungal infection
occurred in 44 patients (44.9%) in the ATG group and 39
patients (35.7%) in the non-ATG group (P ¼ .08). Fifty-fourpatients (55.1%) presented cytomegalovirus (CMV) infection
and 12 (12.2%) with CMV disease in the ATG cohort, and 27
patients (24.8%) presented CMV infection and 9 (8.3%) with
CMV disease in the non-ATG cohort. The incidence of CMV
infectionwas signiﬁcantly higher among the ATG group than
in the non-ATG group (P ¼ .003). Twenty-three patients in
the ATG group and 15 patients in the non-ATG group expe-
rienced leukemia relapse. The 5-year cumulative incidence of
relapse was signiﬁcantly higher in the ATG cohort when
compared with that of the non-ATG cohort (30.7% [95% CI,
22.8% to 38.5%] versus 15.4% [95% CI, 10.9% to 20.6%],
P ¼ .009) (Figure 2B). The causes of death were shown in
Table 2.
Survival
The median follow-up period among survivors was
39 months (range, 15 to 154) for the ATG group patients and
41 months (range, 16 to 152) for the non-ATG group patients
Figure 3. OS and LFS. (A) The 5-year OS for patients in the non-ATG group and
the ATG group was 64.1% (95% CI, 54.4% to 74.2%) and 52.1% (95% CI, 44.6% to
60.5%), respectively (P ¼ .093) (B) The 5-year LFS for patients in the non-ATG
cohort and the ATG cohort was 56.6% (95% CI, 46.5% to 66.8%) and 37.7% (95%
CI, 31.7% to 43.9%), respectively (P ¼ .015).
Figure 2. TRM and relapse. (A) The cumulative incidence of TRM by day 180
was 32.1% (95% CI, 25.5% to 37.8%) and 28% (95% CI, 23.7% to 33.6%) in the ATG
and non-ATG cohorts, respectively (P ¼ .46) (B) The 5-year cumulative inci-
dence of relapse was signiﬁcantly higher in the ATG cohort when compared
with that of the non-ATG cohort (30.7% [95% CI, 22.8% to 38.5%] versus 15.4%
[95% CI, 10.9% to 20.6%]) (P ¼ .009).
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than in the ATG group, although the difference did not reach
statistical signiﬁcance: the 5-year OS for patients in the non-
ATG group and in the ATG group was 64.1% (95% CI, 54.4% toTable 2
Causes of Death
Number of Deaths ATG
(n ¼ 48)
Non-ATG
(n ¼ 38)
Primary graft failure 3 3
Grade III and IV aGVHD 6 10
Severe infection
Bacterial sepsis 3 2
Invasive pulmonary fungal infection 7 6
CMV pneumonia 5 3
Thrombotic microangiopathy 0 2
Disseminated intravascular coagulation 2 0
Hepatic veno-occlusive disease 2 0
Autoimmune hemolytic anemia 2 0
Intracranial hemorrhage 1 0
Pneumothorax 0 2
Multisystem organ failure 2 2
Relapse 15 874.2%) and 52.1% (95% CI, 44.6% to 60.5%), respectively
(P ¼ .093) (Figure 3A). The LFS in the non-ATG cohort was
signiﬁcantly higher than in the ATG cohort: the 5-year LFS for
patients in the non-ATG cohort and the ATG cohort was
56.6% (95% CI, 46.5% to 66.8%) and 37.7% (95% CI, 31.7% to
43.9%), respectively (P ¼ .015) (Figure 3B).DISCUSSION
The efﬁcacy of ATG for GVHD prophylaxis in patients
undergoing unrelated or mismatched allo-HSCT has been
evaluated in several randomized controlled trials and the
data indicated that ATG has a beneﬁcial effect in preventing
GVHD. Kumar et al. [15] performed a systematic review on
the effect of ATG for the prevention of acute GVHD after
related or unrelated allo-HSCT and found that ATG was
effective in preventing grade III and IV aGVHD, but there was
no improvement in TRM or survival. However, Soiffer et al.
[16] examined 1676 adult patients with hematological ma-
lignancies undergoing reduced-intensity conditioning (RIC)
transplantation from related or unrelated donors using
ﬂudarabine-based conditioning regimens, and the risk of
acute GVHD was similar among patients who received either
ATG or a T cellereplete HSCT. Lindemans et al. [17] recently
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evaluate the role of ATG on immune reconstitution and
clinical outcome in children undergoing unrelated CBT, and
the data showed that children who underwent trans-
plantationwithout ATG as part of their conditioning regimen
experienced a remarkably quick immune reconstitution and
signiﬁcantly fewer viral reactivations, but also a higher
probability of severe aGVHD compared with patients who
received ATG; however, the cohort enrolled in the study was
heterogeneous, including those with malignant and
nonmalignant indications, the number of enrolled patients
was relatively small, and the details of TRM and relapse of
malignancies compared between ATG and non-ATG cohorts
were not reported.
The current study indicated that the cumulative incidence
of neutrophil recovery at day 42 were similar between 2
groups, but the cumulative incidence of platelet recovery at
day 100 was signiﬁcantly lower in the ATG cohort than in the
non-ATG cohort. Soiffer et al. [16] also reported that in sibling
or unrelated RIC transplantation, the 28-day probabilities of
neutrophil recovery were similar between recipients of ATG-
containing regimens (94%) and T cellereplete regimens
(96%), but the day 60 probabilities of platelet recovery were
lower with ATG-containing regimens (88%) compared with T
cellereplete regimens (92%) (P ¼ .004). The ATG-Fresenius
Trial Group [5] analyzed 202 patients with hematological
malignancies undergoing unrelated allo-HSCT with and
without ATG and found that the use of additional ATG resulted
in delayed platelet engraftment: engraftment with platelets of
50  109/L or greater at day 100 was achieved in 68.0% of
patients in the ATG-Fresnius group after a median of 37 days
and in 84.7% in the control group (without ATG) after a me-
dian of 20 days (P< .0001). ATG can affect platelet aggregation
and induce thrombocytopenia, and 1 study documented that
patients treated with ATG in an allo-HSCT setting have
an increased probability of developing more severe throm-
bocytopenia and need more platelet transfusions [18]. The
polyclonal ATG contains antibodies speciﬁc to platelet glyco-
proteins V and IIa [18] and can be detected in the recipient’s
plasma up to 60 days after HSCT [17]. In this study, ATG
patients also had signiﬁcantly more CMV infections, which
may affect platelet recovery. Nakamae et al. [19] found that
active CMV infection was a signiﬁcant risk factor for throm-
bocytopenia after day 28 in allo-HSCT (P ¼ .005), suggesting
that active CMV infection was responsible for the delayed
platelet recovery. On the other hand, T cells from the donor
play an important role in facilitating stem cell engraftment in
transplantation of CB, so we speculate that ATG’s capacity to
deplete donor T lymphocytes can affect platelet engraftment
after CBT, and this phenomena might be obvious in the late
use of ATG (days 5 to 0).
Our data showed that there was no difference in the inci-
dence of aGVHD or cGVHD between the ATG and non-ATG
cohort patients, suggesting that our CBT patients cannot
obtain additional protection from ATG in terms of GVHD. The
lower incidence and severity of acute GVHD after CBT might
be attributed to the fewer nucleated cell dose and lower Tcells
allo-reactivity in CB [11]. Because of the concern of increased
risk of infections or decreased disease control with ATG use,
ATG administration is not a uniform practice in the CBT setting
[20]. Although ATG was omitted in conditioning, Takahashi
et al. [8,21] reported that the cumulative incidences of grades
III and IV aGVHD and extensive-type cGVHD among CBT re-
cipients were signiﬁcantly lower than those among related or
unrelated bone marrow/peripheral blood stem cell transplantrecipients, despite the higher HLA mismatching rate in CBT.
Hagen et al. [22] retrospectively studied the effect of ATG in
144 AML patients (34 of whom received ATG) undergoing RIC
CBT or HLA-matched sibling peripheral blood stem cell
transplantations, and found that there were no differences in
aGVHD and cGVHD between ATG and non-ATG patients. A
more recent study [23] also showed that the omission of ATG
before double CBT with RIC did not lead to an increased
incidence of grade III and IV aGVHD (only 14%). However, in
Lindemans’s comparative analysis [17], the aGVHD rate was
higher in the non-ATG group: this might be inﬂuenced by the
more selection of primary immunodeﬁciency patients in non-
ATG group and the authors thought that such children would
be at higher risk of aGVHD because of ongoing infections and
tissue inﬂammation.
Although TRM was comparable between ATG and non-
ATG cohorts, the incidence of CMV infection was signiﬁ-
cantly higher among the ATG group compared with that
among the non-ATG group (P ¼ .003) in our study. Viral in-
fections are a particular challenge after CBT because of the
delayed immune reconstitution, which can be exacerbated
by the use of ATG. Schaenman et al. [24] reported that the
administration of ATG and total lymphoid irradiation resul-
ted in a strikingly earlier viremia after transplantation when
compared with the previously reported timing of viremia
after myeloablative conditioning. The improved immune
reconstitution in patients without ATG could lead to the
lower incidence of virus reactivation after CBT. Lindemans
et al. [17] found that the non-ATG group showed an early
immune reconstitution and a lower number of episodes of
viral reactivations compared with patients who received
ATG. Sauter et al. [25] also reported that double unit CBT
without ATG is associatedwith a prompt Tcell recovery and a
reduced incidence of Epstein-Barr virus and adenovirus in-
fections compared with the published literature.
In the present study, the use of ATG signiﬁcantly increases
the likelihood of disease relapse (30.7% versus 15.4%, P¼ .009),
whichnegativelyaffects LFS (37.7%versus56.6%,P¼ .015).More
evidence indicated that cord bloodederived Tcellswere critical
for the prevention of leukemic relapse, and the GVL effect may
be increased over time as a result of thymic reconstitution after
3 to 6months after CBT [11]. Lindemans et al. [17] indicated that
the only predictor for early immune reconstitution after CBT
was the omission of ATG from the conditioning regimen, and
CD3þ, CD4þ, and CD4þ-naïve T cell numbers were 1 log higher
in thenon-ATGgroup comparedwith theATGgroup at 1, 2, 3, 6,
and 12 months after CBT. ATG with the T cell depletion might
contribute toa reduction in theGVLeffect andan increase in the
relapse incidence. Data from the Center for International Blood
and Marrow Transplant Research [16] showed higher relapse
rate and lower disease-free survival in patients who received
alemtuzumab-containing (51% and30%, respectively) andATG-
containing (49% and 25%, respectively) regimens when
compared with patients who received T cellereplete regimens
(38%and39%, respectively) (P< .001 and P< .001, respectively).
Du et al. [26] conducted a systematic reviewandmeta-analysis
of ATG use in myeloablative HSCT, which included 10 clinical
trials with a total of 1859 patients, and also showed that use of
ATG with an increased incidence of leukemia relapse (relative
risk, 1.28; P ¼ .04). The relationship between GVL and ATG is
probably also dose dependent; that is, a higher ATGdose seems
more effective in reducing the GVL effect compared with the
lower dose. Remberger et al. [27] found, in patients receiving
HLA-matchedunrelated RIC-HSCT, that an ATGdose of 8mg/kg
resulted in a higher incidence of relapse and lower relapse-free
C. Zheng et al. / Biol Blood Marrow Transplant 21 (2015) 707e712712survival compared with an ATG dose of 6 mg/kg (41% versus
19%, P ¼ .04; 61% versus 36%, P ¼ .14) and this effect was most
apparent in patients with high-risk disease (54% versus 10%,
P ¼ .02; 59% versus 23%, P ¼ .04). On the other hand, although
ATG can remove and immobilize T cells and delay T cell recov-
ery, some authors regarded that the decreased GVL effect
caused by ATG can be overcome by increasing the infused cell
dose and presumably by increasing the number of T cells.
Remberger et al. [28] demonstrated that the ATG-treated pa-
tients receiving a nucleated cell dose  10  108/kg had a
relapse incidence of 31% and relapse-free survival of 56%,
compared with 83% (P ¼ .003) and 17% (P ¼ .05) in those
receiving an nucleated cell dose<10 108/kg, in the context of
RIC-HSCT from sibling donors.
In conclusion, the current study demonstrated that, for
patients with high-risk or advanced childhood hematological
malignancies receiving unrelated CBT, those whose condi-
tioning omitted ATG had a comparable GVHD and TRM, a
signiﬁcantly lower relapse risk, and an improved long-term
survival compared with those who received conditioning
including ATG, and the omission of ATG was also associated
with a faster platelet recovery and a lower rate of CMV
infection. However, this was a nonprospective and non-
randomized study. The regimens used in the conditioning
and GVHD prophylaxis are too heterogeneous, and whether
or not to use ATG was also at the discretion of the each
center. We strongly recommend conducting a prospective
randomized clinical trial to evaluate whether the omission of
ATG confers a survival advantage for children with hemato-
logical malignancies receiving unrelated CBT.
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